Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma
Дата публикации: 30-09-2026 07:00:00

Evidence for efficacy is based on the results from the IGNYTE study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma015.4307-10-2026
2Cancer Vaccine Produces 49% Melanoma Reduction in Patients Five Years Later07.9607-06-2026
3FDA approves lutetium Lu 177 vipivotide tetraxetan with ARPI therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer014.7923-09-2026
4No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC016.4124-09-2026
5New mesothelioma drug turns cancer’s own defenses against it09.8917-09-2026
6FDA одобрило комбинацию Welireg и Lenvima для терапии второй линии рака почки010.528-09-2026
7EMA recommends extension of indications for pirtobrutinib08.8625-09-2026
8La vacuna personalizada contra el melanoma encara la prueba definitiva: los datos completos llegarán en octubre06.5321-08-2026
9Injectable nanodevices could provide effective treatment for drug-resistant glioblastoma015.8910-09-2026
10Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS08.7130-09-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 12.14. Источник: www.esmo.org.